MVASI (bevacizumab) | Cancer Treatment | Amgen

You are now leaving MVASI.EU and entering another Amgen website. Would you like to continue?

You are now leaving MVASI.EU and entering another Amgen website. Would you like to continue?

You are now leaving MVASI.EU and entering another Amgen website. Would you like to continue?

Stay on MVASI.EU Continue

The information contained in this website is for European healthcare professionals only

I understand and confirm I am an EU healthcare professional
Read more >
I am not an EU healthcare professional
Read more >
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Introducing MVASI®

MVASI®: THE AMGEN® BEVACIZUMAB THAT GIVES YOU CONFIDENCE AND CONTINUITY OF CARE1,2

MVASI® CAN NOW BE USED FOR YOUR BEVACIZUMAB-ELIGIBLE PATIENTS AND IS APPROVED FOR USE IN THE SAME WAY AS AVASTIN®*†1,2
  • Same tumour types†1,2
  • Highly similar efficacy and safety profile1-3
  • Same pharmaceutical composition, including excipients and pH1-5

WHAT’S BEHIND MVASI®
MAKES THE DIFFERENCE

AMGEN® experience in biologics and science is behind all our products. The Amgen® bevacizumab providing you confidence and continuity.*†1

40 YEARS OF EXPERIENCE IN BIOTECHNOLOGY8

  • MVASI® is our third biosimilar alongside our portfolio of innovative biologics
  • Produced in-house using Amgen®’s end-to-end manufacturing processes
  • Fully committed to reach every patient, every time
Read more >

HERITAGE IN SOLID TUMOURS9-13

  • >15 years Aranesp® and Neulasta® (supportive care)
  • 13 years Vectibix® (mCRC)
  • 9 years XGEVA® (advanced malignancies involving bone)
  • 2 years KANJINTI® (breast & gastric cancer)
Read more >

MVASI® BACKED BY COMPREHENSIVE EVIDENCE FOR BIOEQUIVALENCE TO AVASTIN®2,3

  • Robust totality of evidence
  • Same tumour types*†
  • Same excipients & pH
Read more >

DEDICATED PRESENCE & SUPPORT FROM AMGEN®14

  • Medical & customer support
  • Educational programmes
  • Patient services
Read more >

*MVASI® has been approved as a biosimilar of Avastin® and is dosed and administered in the same way.
†The MVASI® therapeutic indications do not include use in combination with paclitaxel for patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
mCRC = metastatic colorectal cancer.
References:
  1. MVASI® (bevacizumab) EU Summary of Product characteristics. August 2020.
  2. Avastin® (bevacizumab) EU Summary of Product characteristics. March 2020.
  3. EMA. Committee for Medicinal Products for Human Use (CHMP). MVASI Assessment Report, EMA/798844/2017. Nov 2017.
  4. MVASI® (bevacizumab) US prescribing information. June 2019.
  5. Avastin® (bevacizumab) US prescribing information. June 2019.
  6. Amgen® Inc. Annual Report, Form 10-K 2018. Available at: https://www.sec.gov/Archives/edgar/data/318154/000031815419000008/amgn-12312018x10kq42018.htm [accessed 29 January 2020].
  7. Data on file.
  8. Amgen® website. Available at: https://www.amgen.com/science/ [accessed 14 January 2020].
  9. ARANESP® (darbepoetin alfa) Summary of Product Characteristics. Jan 2020.
  10. NEULASTA® (pegfilgrastim) Summary of Product Characteristics. Nov 2019.
  11. VECTIBIX® (panitumumab) Summary of Product Characteristics. Jan 2020.
  12. XGEVA® (denosumab) Summary of Product Characteristics. June 2019.
  13. KANJINTI® (trastuzumab) Summary of Product Characteristics. Nov 2019.
  14. Amgen® solution-oriented services. Available at: https://www.amgenbiosimilars.com/support/solution-oriented-services/ [accessed 14 January 2020].

banner